Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

  • Discontinued
  • GID-TA10422
Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.